Cordis Corporation has announced the launch of its Saber percutaneous transluminal angioplasty (PTA) dilatation catheter for the treatment of patients with peripheral arterial disease. The Saber catheter is cleared for use and now available in Europe, the United States and Japan. According to Cordis, this newproduct offers outstanding crossability and a comprehensive offering of balloon sizes on the widely-used .018” over-the-wire platform. Physicians can now treat a wider range of peripheral arterial disease patients with a single balloon brand.
Developed to complement the Cordis PTA portfolio as a next-generation, high-performance workhorse .018” PTA balloon catheter, Saber catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature.
Saber catheter is available in balloon diameters of 2-10mm and lengths of 20-300mm. Saber catheter combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with trusted Duralyn Material.
“In my initial experience with Saber catheter, I see outstanding crossability in very tight lesions as well as excellent deflation times,” says Peter Goverde, ZNA Antwerpen in Brussels, Belgium. “Given these performance characteristics combined with the size offering that Saber catheter provides, I see the value in adopting this as the preferred .018” workhorse balloon in my practice.”
